“medivation” Archives

in
Entry Author Date Location
Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More 08/26/16 National
Pfizer Shells Out $14B to Win Medivation Sweepstakes 08/22/16 San Francisco
OncoGenex Hires Advisor, Evaluates Options As Cancer Drug Fails Again 08/16/16 Seattle
Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares Crumble 07/26/16 Boston
Biotech Roundup: Fighting Addiction, Obama Precision, Juno Deaths & More 07/08/16 National
Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More 06/10/16 National
Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More 05/27/16 National
West Coast Biotech Roundup: Acadia, Medivation, Verily, and More 05/06/16 San Diego
East Coast Biotech Roundup: Homology, Biogen, Intellia & More 05/05/16 Boston
In M&A Bonanza, AbbVie, Sanofi Throw Billions at Stemcentrx, Medivation 04/28/16 San Francisco
West Coast Biotech Roundup: Theranos, Medivation, Juno, and More 04/15/16 San Francisco
West Coast Bio Roundup: UCLA Cashes In, BioMarin Tries Again & More 03/04/16 San Francisco
Stealthy MIT Spinout Ribon, Led by a Sanofi Vet, Takes Aim at Cancer 03/03/16 Boston
Led By Biotech Stars, ORIC Nabs $53M To Fight Drug-Resistant Cancer 12/02/15 San Francisco
West Coast Biotech Roundup: BioMarin, Tocagen, Medivation, Twelve 08/27/15 San Diego
Innocrin Pharmaceuticals Lands $28M for Prostate, Breast Cancer Trials 04/15/15 Raleigh Durham
As Huge Bills Loom, Immunotherapy Pioneer Dendreon Enters Bankruptcy 11/10/14 Seattle
Tokai Bags $97M For Prostate Cancer Drug in Upsized IPO 09/17/14 Boston
West Coast Biotech Roundup: Gates, Orexigen, Medivation & More 09/12/14 Seattle
Exelixis Axes 70% of Workforce as Cancer Drug Flops, Shares Routed 09/02/14 San Francisco
East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More 08/15/14 Boston
Tokai, Chasing the Field in Prostate Cancer, Files For IPO 08/12/14 Boston
West Coast Biotech Roundup: Seragon, Ambrx, Pregenen, and More 07/03/14 San Diego
As Its Investors Reap Returns, venBio Aims for a Bigger Second Fund 06/10/14 San Francisco
OncoGenex Retrenches, and Searches for Answers, After Failed Trial 05/22/14 Seattle
OncoGenex’s Long Wait For Cancer Drug Ends With a Phase 3 Stumble 04/28/14 Seattle
What Biotech Pros Will Be Chirping About at JP Morgan This Week 01/13/14 National
3 Life Sciences Companies That Are Built to Last 12/02/13 National
Dendreon Cuts 150 Jobs, As Prostate Cancer Drug Sales Decline 11/12/13 Seattle
Arno, With Potential Suitor in Opko, Goes After Endometrial Cancer 11/06/13 New York
Page 1 of 3 next page »